Therapeutic drug monitoring in the treatment of invasive aspergillosis with voriconazole in cancer patients--an evidence-based approach (Q38362057)

2 September 2017

1 reference

title

Therapeutic drug monitoring in the treatment of invasive aspergillosis with voriconazole in cancer patients--an evidence-based approach (English)

1 reference

2 September 2017

0 references

invasive aspergillosis

1 reference

1 reference

3

Hans-Peter Lipp

1 reference

2 September 2017

2

Thomas Lehrnbecher

1 reference

2 September 2017

5

Dieter Buchheidt

1 reference

2 September 2017

1

Meinolf Karthaus

1 reference

2 September 2017

Stefan Kluge

4

1 reference

2 September 2017

language of work or name

1 reference

20 February 2015

1 reference

2 September 2017

1 reference

2 September 2017

volume

94

1 reference

2 September 2017

issue

4

1 reference

2 September 2017

page(s)

547-556

1 reference

Invasive aspergillosis: new insights into disease, diagnostic and treatment

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

Voriconazole versus amphotericin B for invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3--2009 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

Recent advances in the treatment of life-threatening, invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

Optimizing antifungal choice and administration.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

Practice guidelines for therapeutic drug monitoring of voriconazole: a consensus review of the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

Pharmacokinetic/pharmacodynamic profile of voriconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

Fungal infections associated with contaminated methylprednisolone in Tennessee.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

Clinical importance of the CYP2C19*17 variant allele for voriconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

Pharmacokinetic variability of voriconazole and N-oxide voriconazole measured as therapeutic drug monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

Determination of CYP2C19 phenotype in black Americans with omeprazole: correlation with genotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

Modulators of very low voriconazole concentrations in routine therapeutic drug monitoring.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

A case report of voriconazole therapy failure in a homozygous ultrarapid CYP2C19*17/*17 patient comedicated with carbamazepine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

Importance of voriconazole therapeutic drug monitoring in pediatric cancer patients with invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

Evaluation of the effect of obesity on voriconazole serum concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

Comprehensive in vitro analysis of voriconazole inhibition of eight cytochrome P450 (CYP) enzymes: major effect on CYPs 2B6, 2C9, 2C19, and 3A

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

Tacrolimus use in adult allogeneic stem cell transplant recipients receiving voriconazole: preemptive dose modification and therapeutic drug monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

Safety of triazole antifungal drugs in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

Challenging recommended oral and intravenous voriconazole doses for improved efficacy and safety: population pharmacokinetics-based analysis of adult patients with invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

Comparison of high-performance liquid chromatographic and microbiological methods for determination of voriconazole levels in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

International interlaboratory proficiency testing program for measurement of azole antifungal plasma concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

Population pharmacokinetics of voriconazole in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

Voriconazole therapeutic drug monitoring.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

Voriconazole pharmacokinetics and pharmacodynamics in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

A case-report of unpredictable and massive voriconazole intoxication in a patient with extensive CYP2C19 and CYP2C9 polymorphisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

Voriconazole pharmacokinetics and safety in immunocompromised children compared to adult patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

Voriconazole plasma monitoring.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

Prospective, Observational Study of Voriconazole Therapeutic Drug Monitoring among Lung Transplant Recipients Receiving Prophylaxis: Factors Impacting Levels of and Associations between Serum Troughs, Efficacy, and Toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

Voriconazole therapeutic drug monitoring: retrospective cohort study of the relationship to clinical outcomes and adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

Monitoring plasma voriconazole levels following intravenous administration in critically ill patients: an observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

Serial plasma voriconazole concentrations after allogeneic hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00277-015-2333-Z

10.1007/S00277-015-2333-Z

21 January 2018

Identifiers

DOI

1 reference

2 September 2017

1 reference